The b 1 -adrenoceptor exists in two agonist conformations/states: 1) a high-affinity state where responses to catecholamines and other agonists (e.g., cimaterol) are potently inhibited by b 1 -adrenoceptor antagonists, and 2) a low-affinity secondary conformation where agonist responses, particularly CGP12177 [(2)-4-(3-tert-butylamino-2-hydroxypropoxy)-benzimidazol-2-one] are relatively resistant to inhibition by b 1 -adrenoceptor antagonists. Although both states have been demonstrated in many species (including human), the precise nature of the secondary state is unknown and does not occur in the closely related b 2 -adrenoceptor. Here, using site-directed mutagenesis and functional measurements of production of a cyclic AMP response element upstream of a secreted placental alkaline phosphatase reporter gene and accumulation of 3 H-cAMP, we examined the pharmacological consequences of swapping transmembrane (TM) regions of the human b 1 -and b 2 -adrenoceptors, followed by single point mutations, to determine the key residues involved in the b 1 -adrenoceptor secondary conformation. We found that TM4 (particularly amino acids L195 and W199) had a major role in the generation of the secondary b 1 -adrenoceptor conformation. Thus, unlike at the human b 1 -wild-type adrenoceptor, at b 1 -TM4 mutant receptors, cimaterol and CGP12177 responses were both potently inhibited by antagonists. CGP12177 acted as a simple partial agonist with similar K B and EC 50 values in the b 1 -TM4 but not b 1 -wild-type receptors. Furthermore pindolol switched from a biphasic concentration response at human b 1 -wild-type adrenoceptors to a monophasic concentration response in the b 1 -TM4 mutant receptors. Mutation of these amino acids to those found in the b 2 -adrenoceptor (L195Q and W199Y), or mutation of a single residue (W199D) in the human b 1 -adrenoceptor thus abolished this secondary conformation and created a b 1 -adrenoceptor with only one high-affinity agonist conformation.